低剂量糖皮质激素治疗老年类风湿关节炎的获益、危害与成本:GLORIA试验方案
GLORIA研究是一项为期2年的实用型多中心随机双盲临床试验,评估在标准治疗基础上加用每日5 mg泼尼松龙或安慰剂对≥65岁活动性RA患者的安全性和有效性。主要结局为DAS28的时间平均均值以及严重不良事件或特别关注不良事件的发生。研究旨在为GCs的获益/危害平衡提供证据,并分析成本效果。
要点
- GLORIA试验评估每日5 mg泼尼松龙或安慰剂加标准治疗对老年RA患者的获益与危害。
- 主要结局包括DAS28时间平均均值和严重不良事件或特别关注不良事件的发生。
- 试验允许除GCs外的抗风湿治疗根据临床指征调整,并分析成本效果与效用。
局限性
- 原文述及主要挑战包括对两个主要终点和允许共同干预的实用型试验设计的结果解释。
- 原文述及另一挑战是安全性定义及检测治疗组间差异的相对效力不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints affecting 1% of the world population. It has major impact on patients through disability and associated comorbidities. Current treatment strategies have considerably improved the prognosis, but recent innovations (especially biologic drugs and the new class of so-called "JAK/STAT inhibitors") have important safety issues and are very costly. Glucocorticoids (GCs) are highly effective in RA, and could reduce the need for expensive treatment with biologic agents. However, despite more than 65 years of clinical experience, there is a lack of studies large enough to adequately document the benefit/harm balance. The result is inappropriate treatment strategies, i.e. both under-use and over-use of GCs, and consequently suboptimal treatment of RA. METHODS: The GLORIA study is a pragmatic multicentre, 2-year, randomised, double-blind, clinical trial to assess the safety and effectiveness of a daily dose of 5 mg prednisolone or matching placebo added to standard of care in elderly patients with RA. Eligible participants are diagnosed with RA, have inadequate disease control (disease activity score, DAS28 ≥ 2.6), and are ≥ 65 years. The primary outcome measures are the time-averaged mean value of the DAS28 and the occurrence of serious adverse events or adverse events of special interest. During the trial, change in antirheumatic therapy is permitted as clinically indicated, except for GCs. Cost-effectiveness and cost-utility are secondary outcomes. The main challenge is the interpretation of the trial result with two primary endpoints and the pragmatic trial design that allows co-interventions. Another challenge is the definition of safety and the relative lack of power to detect differences between treatment groups. We have chosen to define safety as the number of patients experiencing at least one serious adverse event. We also specify a decision tree to guide our conclusion on the balance of benefit and harm, and our methodology to combat potential confounding caused by co-interventions. DISCUSSION: Pragmatic trials minimise impact on daily practice and maximise clinical relevance of the results, but analysis and interpretation of the results is challenging. We expect that the results of this trial are of importance for all rheumatologists who treat elderly patients with RA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02585258 . Registered on 20 October 2015.
引用
- Hartman L, Rasch LA, Klausch T, et al. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials. 2018. PMID: 29370811. doi:10.1186/s13063-017-2396-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。